Park City Group Declares Quarterly Cash Dividend

SALT LAKE CITY--(BUSINESS WIRE)-- Park City Group, Inc. (NASDAQ: PCYG), the parent company of ReposiTrak, Inc., which operates a B2B ecommerce, compliance, and supply chain platform that largely partners with grocery retailers, wholesalers, and their suppliers, to accelerate sales, control risk, improve supply chain efficiencies, and source hard-to-find items, announced today that the Company’s Board of Directors has declared a quarterly cash dividend of $0.015 per share ($0.06 per year), payable to shareholders of record on February 15, 2023. The cash dividends will be paid to shareholders of record on or about February 21, 2023.

Specific disclosure relating to Park City Group, including management's analysis of results from operations and financial condition, are contained in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2022 and other reports filed with the Securities and Exchange Commission. Investors are encouraged to read and consider such disclosure and analysis contained in the Company's Form 10-K and other reports, including the risk factors contained in the Form 10-K.

About Park City Group:

Park City Group, Inc. (NASDAQ: PCYG), the parent company of ReposiTrak, Inc., a compliance, supply chain, and e-commerce platform that enables retailers, wholesalers, and their suppliers, to accelerate sales, control risk, and improve supply chain efficiencies. More information is available at www.parkcitygroup.com and www.repositrak.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230210005351/en/

Investor Relations:
John Merrill, CFO
[email protected]
or
FNK IR
Rob Fink
646-809-4048
[email protected]

Source: Park City Group, Inc.

You May Also Be Interested In

• ComEd Debuts Mobile Assistance Unit at Waukegan Resource Fair, Bringing On-Site Bill Help Directly to Customers
• ComEd Sending More Than 60 Employees to Assist NIPSCO with Restoration Work
• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate